Abstract
LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have